{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:47:37Z","timestamp":1792025257314,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009252","name":"Science for Life Laboratory","doi-asserted-by":"publisher","award":["SLL2019\/9"],"award-info":[{"award-number":["SLL2019\/9"]}],"id":[{"id":"10.13039\/501100009252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r Strategisk Forskning","doi-asserted-by":"publisher","award":["FFL-0043"],"award-info":[{"award-number":["FFL-0043"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["220474JIA; 232656Pj"],"award-info":[{"award-number":["220474JIA; 232656Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-01461"],"award-info":[{"award-number":["2022-01461"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022MH085"],"award-info":[{"award-number":["ZR2022MH085"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science Foundation of Jinan City","award":["202134027"],"award-info":[{"award-number":["202134027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint blockade (ICB) has demonstrated limited efficacy in microsatellite stable (MSS) colorectal cancer (CRC). The fibroblast growth factor receptor (FGFR) signaling pathway contributes to tumor immune evasion, yet its role in CRC remains insufficiently understood. We investigated the immunomodulatory effects of FGFR inhibition in combination with PD-1 blockade in murine CRC models. In vitro co-culture systems were used to evaluate T cell activation upon FGFR3 blockade. RNA sequencing and bioinformatics analyses, including The Cancer Genome Atlas (TCGA) dataset evaluation, were conducted to elucidate molecular mechanisms and clinical relevance. Combined FGFR inhibition and PD-1 blockade significantly reduced T cell exhaustion and promoted macrophage repolarization toward an antitumor phenotype. Transcriptomic profiling revealed upregulation of immune-related pathways and activation of immune-stimulatory genes. In vitro, FGFR3-specific monoclonal antibody treatment enhanced IFNg release following PD-1 blockade. Moreover, analysis of TCGA data demonstrated that high\n                    <jats:italic>FGFR3<\/jats:italic>\n                    expression correlates with worse prognosis in CRC patients. Our findings suggest that FGFR pathway inhibition may enhance the efficacy of immune checkpoint blockade and provide a rationale for further investigation of FGFR-targeted combination strategies in MSS CRC.\n                  <\/jats:p>","DOI":"10.1186\/s12885-026-17105-9","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:44:50Z","timestamp":1791927890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhou","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3933-3721","authenticated-orcid":false,"given":"Changqing","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"R\u00fabies Bed\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irineos","family":"Papakyriacou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuezhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"17105_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","volume":"31","author":"SS Jiang","year":"2023","unstructured":"Jiang SS, Xie YL, Xiao XY, Kang ZR, Lin XL, Zhang L, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023;31:781\u2013797.e789. https:\/\/doi.org\/10.1016\/j.chom.2023.04.010","journal-title":"Cell Host Microbe"},{"key":"17105_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ccell.2024.06.009","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wang D, Li Y, Qi L, Si W, Bo Y, et al. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell. 2024;42:1268\u20131285.e1267. https:\/\/doi.org\/10.1016\/j.ccell.2024.06.009","journal-title":"Cancer Cell"},{"key":"17105_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei L, Liu Y, Liu L, Gao S, Gao X, Feng Y, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22:29 https:\/\/doi.org\/10.1186\/s12943-023-01731-z","journal-title":"Mol Cancer"},{"key":"17105_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-021-00569-4","volume":"19","author":"K Ganesh","year":"2022","unstructured":"Ganesh K. Optimizing immunotherapy for colorectal cancer. Nat Rev Gastroenterol Hepatol. 2022;19:93\u201394. https:\/\/doi.org\/10.1038\/s41575-021-00569-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"17105_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/1078-0432.Ccr-23-2213","volume":"30","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Qin G, Bai F, Wu X, Ke H, et al. Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer. Clin Cancer Res. 2024;30:368\u201378. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2213","journal-title":"Clin Cancer Res"},{"key":"17105_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/jco.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41:678\u2013700. https:\/\/doi.org\/10.1200\/jco.22.01690","journal-title":"J Clin Oncol"},{"key":"17105_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/jco.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022;40:161\u201370. https:\/\/doi.org\/10.1200\/jco.21.01015","journal-title":"J Clin Oncol"},{"key":"17105_CR8","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andre","year":"2024","unstructured":"Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, et al. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024;391:2014\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2402141","journal-title":"N Engl J Med"},{"key":"17105_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361\u201375. https:\/\/doi.org\/10.1038\/s41575-019-0126-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"17105_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. Jama. 2023;329:1271\u201382. https:\/\/doi.org\/10.1001\/jama.2023.4428","journal-title":"Jama"},{"key":"17105_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402:41\u201353. https:\/\/doi.org\/10.1016\/s0140-6736(23)00772-9","journal-title":"Lancet"},{"key":"17105_CR12","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41586-023-06155-9","volume":"618","author":"L Chen","year":"2023","unstructured":"Chen L, Fu L, Sun J, Huang Z, Fang M, Zinkle A, et al. Structural basis for FGF hormone signalling. Nature. 2023;618:862\u201370. https:\/\/doi.org\/10.1038\/s41586-023-06155-9","journal-title":"Nature"},{"key":"17105_CR13","doi-asserted-by":"publisher","unstructured":"Chen, G, Chen, L, Li, X, and Mohammadi, M (2025). FGF-based drug discovery: advances and challenges. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/s41573-024-01125-w.","DOI":"10.1038\/s41573-024-01125-w"},{"key":"17105_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.712107","volume":"12","author":"P Adam","year":"2021","unstructured":"Adam P, Kircher S, Sbiera I, Koehler VF, Berg E, Kn\u00f6sel T, et al. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. Front Endocrinol (Lausanne). 2021;12:712107 https:\/\/doi.org\/10.3389\/fendo.2021.712107","journal-title":"Front Endocrinol (Lausanne)"},{"key":"17105_CR15","doi-asserted-by":"publisher","unstructured":"Zhang, W, Tong, S, Hu, B, Wan, T, Tang, H, Zhao, F, et al. (2023). Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J Immunother Cancer 11. https:\/\/doi.org\/10.1136\/jitc-2023-007366.","DOI":"10.1136\/jitc-2023-007366"},{"key":"17105_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.tem.2022.04.009","volume":"33","author":"V Vella","year":"2022","unstructured":"Vella V, De Francesco EM, Bonavita E, Lappano R, Belfiore A. IFN-I signaling in cancer: the connection with dysregulated Insulin\/IGF axis. Trends Endocrinol Metab. 2022;33:569\u201386. https:\/\/doi.org\/10.1016\/j.tem.2022.04.009","journal-title":"Trends Endocrinol Metab"},{"key":"17105_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","volume":"33","author":"EN Chin","year":"2023","unstructured":"Chin EN, Sulpizio A, Lairson LL. Targeting STING to promote antitumor immunity. Trends Cell Biol. 2023;33:189\u2013203. https:\/\/doi.org\/10.1016\/j.tcb.2022.06.010","journal-title":"Trends Cell Biol"},{"key":"17105_CR18","doi-asserted-by":"publisher","unstructured":"Nagarajan, D, Parracho, RT, Corujo, D, Xie, M, Kutkaite, G, Olsen, TK, et al. (2024). Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma. J Clin Invest 134. https:\/\/doi.org\/10.1172\/jci175310.","DOI":"10.1172\/jci175310"},{"key":"17105_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25\u201339. https:\/\/doi.org\/10.1038\/s41577-019-0218-4","journal-title":"Nat Rev Immunol"},{"key":"17105_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47987-x","volume":"15","author":"I Papakyriacou","year":"2024","unstructured":"Papakyriacou I, Kutkaite G, R\u00fabies Bed\u00f3s M, Nagarajan D, Alford LP, Menden MP, et al. Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer. Nat Commun. 2024;15:3581 https:\/\/doi.org\/10.1038\/s41467-024-47987-x","journal-title":"Nat Commun"},{"key":"17105_CR21","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00262-020-02544-5","volume":"69","author":"M Natoli","year":"2020","unstructured":"Natoli M, Bonito N, Robinson JD, Ghaem-Maghami S, Mao Y. Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade. Cancer Immunol Immunother. 2020;69:1391\u2013401. https:\/\/doi.org\/10.1007\/s00262-020-02544-5","journal-title":"Cancer Immunol Immunother"},{"key":"17105_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","volume":"17","author":"Y Chen","year":"2024","unstructured":"Chen Y, Dai S, Cheng CS, Chen L. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J Hematol Oncol. 2024;17:130 https:\/\/doi.org\/10.1186\/s13045-024-01647-1","journal-title":"J Hematol Oncol"},{"key":"17105_CR23","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","volume":"41","author":"J Li","year":"2023","unstructured":"Li J, Wu C, Hu H, Qin G, Wu X, Bai F, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell. 2023;41:1152\u20131169.e1157. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.011","journal-title":"Cancer Cell"},{"key":"17105_CR24","doi-asserted-by":"publisher","unstructured":"Liu, C, Liu, R, Wang, B, Lian, J, Yao, Y, Sun, H, et al. (2021). Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer 9. https:\/\/doi.org\/10.1136\/jitc-2020-001895.","DOI":"10.1136\/jitc-2020-001895"},{"key":"17105_CR25","doi-asserted-by":"publisher","unstructured":"Zhou, Y, Zhang, W, Wang, B, Wang, P, Li, D, Cao, T, et al. (2024). Mitochondria-targeted photodynamic therapy triggers GSDME-mediated pyroptosis and sensitizes anti-PD-1 therapy in colorectal cancer. J Immunother Cancer 12. https:\/\/doi.org\/10.1136\/jitc-2023-008054.","DOI":"10.1136\/jitc-2023-008054"},{"key":"17105_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13046-021-02043-0","volume":"40","author":"D Doleschel","year":"2021","unstructured":"Doleschel D, Hoff S, Koletnik S, Rix A, Zopf D, Kiessling F, et al. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J Exp Clin Cancer Res. 2021;40:288 https:\/\/doi.org\/10.1186\/s13046-021-02043-0","journal-title":"J Exp Clin Cancer Res"},{"key":"17105_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08974-3","volume":"21","author":"Y Sato","year":"2021","unstructured":"Sato Y, Fu Y, Liu H, Lee MY, Shaw MH. Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. BMC Cancer. 2021;21:1222 https:\/\/doi.org\/10.1186\/s12885-021-08974-3","journal-title":"BMC Cancer"},{"key":"17105_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-190","volume":"15","author":"JC Castle","year":"2014","unstructured":"Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics. 2014;15:190 https:\/\/doi.org\/10.1186\/1471-2164-15-190","journal-title":"BMC Genomics"},{"key":"17105_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1102282","volume":"14","author":"B Schr\u00f6rs","year":"2023","unstructured":"Schr\u00f6rs B, Hos BJ, Yildiz IG, L\u00f6wer M, Lang F, Holtstr\u00e4ter C, et al. MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression. Front Immunol. 2023;14:1102282 https:\/\/doi.org\/10.3389\/fimmu.2023.1102282","journal-title":"Front Immunol"},{"key":"17105_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10147-019-01520-z","volume":"25","author":"R Saito","year":"2020","unstructured":"Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. Int J Clin Oncol. 2020;25:831\u201341. https:\/\/doi.org\/10.1007\/s10147-019-01520-z","journal-title":"Int J Clin Oncol"},{"key":"17105_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining \u2018T cell exhaustion. Nat Rev Immunol. 2019;19:665\u201374. https:\/\/doi.org\/10.1038\/s41577-019-0221-9","journal-title":"Nat Rev Immunol"},{"key":"17105_CR32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","volume":"23","author":"K Chamoto","year":"2023","unstructured":"Chamoto K, Yaguchi T, Tajima M, Honjo T. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nat Rev Immunol. 2023;23:682\u201395. https:\/\/doi.org\/10.1038\/s41577-023-00867-9","journal-title":"Nat Rev Immunol"},{"key":"17105_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300299","volume":"10","author":"AI Matos","year":"2023","unstructured":"Matos AI, Peres C, Carreira B, Moura LIF, Ac\u00farcio RC, Vogel T, et al. Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors. Adv Sci (Weinh). 2023;10:e2300299 https:\/\/doi.org\/10.1002\/advs.202300299","journal-title":"Adv Sci (Weinh)"},{"key":"17105_CR34","doi-asserted-by":"publisher","unstructured":"Sugiyarto, G, Lau, D, Hill, SL, Arcia-Anaya, D, Boulanger, DSM, Parkes, E, et al. (2023). Reactivation of low avidity tumor-specific CD8(+) T cells associates with immunotherapeutic efficacy of anti-PD-1. J Immunother Cancer 11. https:\/\/doi.org\/10.1136\/jitc-2023-007114.","DOI":"10.1136\/jitc-2023-007114"},{"key":"17105_CR35","doi-asserted-by":"publisher","unstructured":"Quan, Y, He, J, Zou, Q, Zhang, L, Sun, Q, Huang, H, et al. (2023). Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer. J Immunother Cancer 11. https:\/\/doi.org\/10.1136\/jitc-2023-007080.","DOI":"10.1136\/jitc-2023-007080"},{"key":"17105_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ccell.2025.01.001","volume":"43","author":"X Guo","year":"2025","unstructured":"Guo X, Nie H, Zhang W, Li J, Ge J, Xie B, et al. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell. 2025;43:248\u2013268.e249. https:\/\/doi.org\/10.1016\/j.ccell.2025.01.001","journal-title":"Cancer Cell"},{"key":"17105_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","volume":"17","author":"B Toledo","year":"2024","unstructured":"Toledo B, Zhu Chen L, Paniagua-Sancho M, Marchal JA, Per\u00e1n M, Giovannetti E. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. J Hematol Oncol. 2024;17:44 https:\/\/doi.org\/10.1186\/s13045-024-01559-0","journal-title":"J Hematol Oncol"},{"key":"17105_CR38","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","volume":"21","author":"J Kzhyshkowska","year":"2024","unstructured":"Kzhyshkowska J, Shen J, Larionova I. Targeting of TAMs: can we be more clever than cancer cells? Cell Mol Immunol. 2024;21:1376\u2013409. https:\/\/doi.org\/10.1038\/s41423-024-01232-z","journal-title":"Cell Mol Immunol"},{"key":"17105_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17914-x","volume":"11","author":"JH Im","year":"2020","unstructured":"Im JH, Buzzelli JN, Jones K, Franchini F, Gordon-Weeks A, Markelc B, et al. FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy. Nat Commun. 2020;11:4064 https:\/\/doi.org\/10.1038\/s41467-020-17914-x","journal-title":"Nat Commun"},{"key":"17105_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1390453","volume":"15","author":"L Shen","year":"2024","unstructured":"Shen L, Li Y, Zhao H. Fibroblast growth factor signaling in macrophage polarization: impact on health and diseases. Front Immunol. 2024;15:1390453 https:\/\/doi.org\/10.3389\/fimmu.2024.1390453","journal-title":"Front Immunol"},{"key":"17105_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/0008-5472.Can-20-2426","volume":"82","author":"Y Adachi","year":"2022","unstructured":"Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S, et al. Inhibition of FGFR Reactivates IFN\u03b3 Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. Cancer Res. 2022;82:292\u2013306. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-2426","journal-title":"Cancer Res"},{"key":"17105_CR42","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664\u201371. https:\/\/doi.org\/10.1002\/ijc.23131","journal-title":"Int J Cancer"},{"key":"17105_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N Engl J Med"},{"key":"17105_CR44","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(18)30207-1","journal-title":"Lancet"},{"key":"17105_CR45","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021;384:1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"key":"17105_CR46","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/s1470-2045(23)00276-0","volume":"24","author":"L Albiges","year":"2023","unstructured":"Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023;24:881\u201391. https:\/\/doi.org\/10.1016\/s1470-2045(23)00276-0","journal-title":"Lancet Oncol"},{"key":"17105_CR47","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC. Hepatology. 2021;74:2544\u201360. https:\/\/doi.org\/10.1002\/hep.31921","journal-title":"Hepatology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-17105-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-17105-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-17105-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:21:55Z","timestamp":1792023715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-17105-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["17105"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-17105-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in compliance with all applicable ethical regulations and was approved by the Review Committee of Shandong First Medical University Affiliated Provincial Hospital (Shandong Provincial Hospital; Approval No.: No.2023-065). Mice were euthanized via intraperitoneal injection of diluted overdose pentobarbital sodium (150\u2009mg\/kg, diluted with isotonic saline). Complete loss of all withdrawal reflexes and permanent cessation of breathing and heartbeat were fully confirmed before tissue dissection. This single-step lethal anesthesia minimizes animal procedural suffering and complies strictly with the AVMA euthanasia recommendations and ARRIVE 2.0 reporting guidelines. All authors are informed and agree to participate in this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1227"}}